Emmert Roberts1, A Eden Evins2, Ann McNeill3, Debbie Robson4. 1. Academic Clinical Fellow in Psychiatry, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 2. William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School, Boston, MA, USA. 3. Professor of Tobacco Addiction, National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 4. Senior Post-Doctorate Researcher in Tobacco Addiction, National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Abstract
BACKGROUND AND AIMS: To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. METHOD: We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials from database inception to 1 December 2014 for randomized controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking. Pharmacotherapies included nicotine replacement therapy (NRT), bupropion and varenicline delivered as monotherapy or in combination compared with each other or placebo. The efficacy outcome was self-reported sustained smoking cessation, verified biochemically at the longest reported time-point. The tolerability outcome was number of patients discontinuing the trial due to any adverse event. RESULTS: Seventeen study reports were included, which represented 14 individual RCTs. No trials were found in patients with depressive psychoses, delusional disorder or that compared NRT monotherapy with placebo. A total of 356 and 423 participants were included in the efficacy and tolerability analyses, respectively. From the network meta-analysis, both bupropion and varenicline were more effective than placebo [odds ratio (OR) = 4.51, 95% credible interval (CrI) = 1.45-14.04 and OR = 5.17, 95% CrI = 1.78-15.06, respectively]. Data were insensitive to an assessment of varenicline versus bupropion (OR = 1.15, 95% CrI = 0.24-5.45). There were no significant differences in tolerability. All outcomes were rated by GRADE criteria as very low quality. CONCLUSIONS: The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.
BACKGROUND AND AIMS: To assess the efficacy and tolerability of adjunctive pharmacotherapy for smoking cessation in adults with serious mental illness (SMI) by means of a systematic review and network meta-analysis. METHOD: We searched Embase, Medline, PsychINFO and the Cochrane Central Register of Controlled Trials from database inception to 1 December 2014 for randomized controlled trials (RCTs) published in English. We included all studies of smokers with SMI (including schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder and depressive psychoses) who were motivated to quit smoking. Pharmacotherapies included nicotine replacement therapy (NRT), bupropion and varenicline delivered as monotherapy or in combination compared with each other or placebo. The efficacy outcome was self-reported sustained smoking cessation, verified biochemically at the longest reported time-point. The tolerability outcome was number of patients discontinuing the trial due to any adverse event. RESULTS: Seventeen study reports were included, which represented 14 individual RCTs. No trials were found in patients with depressive psychoses, delusional disorder or that compared NRT monotherapy with placebo. A total of 356 and 423 participants were included in the efficacy and tolerability analyses, respectively. From the network meta-analysis, both bupropion and varenicline were more effective than placebo [odds ratio (OR) = 4.51, 95% credible interval (CrI) = 1.45-14.04 and OR = 5.17, 95% CrI = 1.78-15.06, respectively]. Data were insensitive to an assessment of varenicline versus bupropion (OR = 1.15, 95% CrI = 0.24-5.45). There were no significant differences in tolerability. All outcomes were rated by GRADE criteria as very low quality. CONCLUSIONS: The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.
Authors: L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye Journal: Arch Gen Psychiatry Date: 2011-08-01
Authors: Sarah M Hartz; Carlos N Pato; Helena Medeiros; Patricia Cavazos-Rehg; Janet L Sobell; James A Knowles; Laura J Bierut; Michele T Pato Journal: JAMA Psychiatry Date: 2014-03 Impact factor: 21.596
Authors: Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly Journal: Schizophr Res Date: 2011-03-04 Impact factor: 4.939
Authors: C R Breese; M J Lee; C E Adams; B Sullivan; J Logel; K M Gillen; M J Marks; A C Collins; S Leonard Journal: Neuropsychopharmacology Date: 2000-10 Impact factor: 7.853
Authors: Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George Journal: J Clin Psychiatry Date: 2012-05 Impact factor: 4.384
Authors: Andrea H Weinberger; Jennifer C Vessicchio; Kristi A Sacco; Cerissa L Creeden; K N Roy Chengappa; Tony P George Journal: J Clin Psychopharmacol Date: 2008-10 Impact factor: 3.153
Authors: Li-Shiun Chen; Timothy B Baker; Jeanette M Korpecki; Kelly E Johnson; Jaime P Hook; Ross C Brownson; Laura J Bierut Journal: Psychiatr Serv Date: 2018-06-01 Impact factor: 3.084
Authors: Randi M Schuster; Corinne Cather; Gladys N Pachas; Haiyue Zhang; Kristina M Cieslak; Susanne S Hoeppner; David Schoenfeld; A Eden Evins Journal: Addict Behav Date: 2017-02-24 Impact factor: 3.913
Authors: A Eden Evins; Neal L Benowitz; Robert West; Cristina Russ; Thomas McRae; David Lawrence; Alok Krishen; Lisa St Aubin; Melissa Culhane Maravic; Robert M Anthenelli Journal: J Clin Psychopharmacol Date: 2019 Mar/Apr Impact factor: 3.153
Authors: Li-Shiun Chen; Timothy Baker; Ross C Brownson; Robert M Carney; Douglas Jorenby; Sarah Hartz; Nina Smock; Mark Johnson; Douglas Ziedonis; Laura J Bierut Journal: Community Ment Health J Date: 2016-11-30
Authors: Sara Kalkhoran; Anne N Thorndike; Nancy A Rigotti; Vicki Fung; Travis P Baggett Journal: J Gen Intern Med Date: 2019-02-19 Impact factor: 5.128
Authors: Panagiotis Spanakis; Emily Peckham; Ben Young; Paul Heron; Della Bailey; Simon Gilbody Journal: Addiction Date: 2021-11-06 Impact factor: 7.256